The global regulatory framework surrounding psychedelic-assisted therapies is moving at an unprecedented pace. Over the last few years, clinical advancements have forced legislative bodies to reconsider compounds once classified strictly as prohibited substances. While public attention often lands on psilocybin or MDMA, a far more intense and biologically unique alkaloid is driving critical legal debates: […]